IBS has classically been regarded as a “diagnosis of exclusion,” but new research suggested that might be changing with better diagnostic and treatment approaches.
Alopecia areata was more likely to develop in patients with inflammatory bowel disease (IBD) who were taking anti–tumor necrosis factor (TNF) therapy at the onset of the condition.